GLP Watchdog

Best Direct Primary Care GLP-1 Providers in 2026 — Ranked & Reviewed

Insurance billing comes out of the model entirely in Direct Primary Care (DPC), replaced by a flat monthly fee paid to the practice. A small and growing set of DPC practices now put GLP-1 weight-loss medication inside that membership at wholesale or close to it. Set that against the direct-to-consumer marketplace pattern, where the medication alone runs $300-$500/month and no continuing primary-care relationship comes with it. Lab monitoring, dose adjustments and side-effect management all sit inside one ongoing provider relationship here, which most clinicians treat as the standard to aim for in chronic weight management. Expect a membership fee of $50-$150/month, with wholesale GLP-1 on top at $65-$300/month depending on the drug, the dose and the form. Where insurance will not cover brand-name Wegovy or Zepbound, this can be the cheapest total path to a GLP-1 plus comprehensive care.

1 provider compared

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed

1 direct primary care glp-1 providers compared · independently scored against our six-factor methodology.

Quick Picks: Top 1

#ProviderScore
1Primary Clinic (Direct GLP)Visit
6weighted dimensions
1direct primary care glp-1 providers compared
Everychecked against the seller's own site
Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →

Detailed Reviews

1

Primary Clinic (Direct GLP)

Best for: seeing what it charges before you answer any medical questions

6.6

What is sold here is Direct Primary Care membership, not a GLP-1 package. $89/mo covers primary care without limit, texting the clinic directly, virtual visits the same day and routine labs. Members then purchase compounded 503A GLP-1s at wholesale, no markup applied: $65/mo and up for semaglutide, $110/mo and up for tirzepatide. It runs in 10 states so far, and monitoring of the medication happens inside a continuing care relationship.

Score Breakdown

Value25%
3
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
8.5
Accessibility10%
3.6
Support10%
5

Pros

  • ✓Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • ✓We found no FDA warning letters issued to Primary Clinic (Direct GLP)

Cons

  • ✗Serves only 10 states, so check that yours is one of them
  • ✗Ask which pharmacy fills the prescription before you pay, so you can check its license
  • ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Starting from $65/moRead full review →
Visit Primary Clinic (Direct GLP) →
How we rank, and what counts as “legit”

Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.

Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].

How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Frequently Asked Questions

A membership model, in which a flat monthly or annual fee goes straight to the practice and buys unlimited access to a physician, with no insurance middleman in between. Applied to GLP-1s, that means a continuing clinician relationship, labs, and prescribing, often with medication pricing you can read, in place of a one-off telehealth transaction.
It can be, particularly where ongoing clinical care matters to you. Unlimited visits and monitoring sit inside one predictable fee, and many practices pass medication through at or near cost. Whether the total comes out lower depends on how much support you use against what a pay-per-visit telehealth provider would charge. Compare the totals in the list above.
No. Operating outside insurance is the design, and payment goes to the practice directly. For GLP-1 care that is much of the appeal: membership-based pricing you can read, with no prior authorizations to clear. Labs or specialist referrals can still go through insurance separately, where you carry it.
Six weighted dimensions produce the score. Value (25%) and Effectiveness (25%) carry the most, then User Experience (15%) and Trust & Safety (15%), then Accessibility (10%) and Support (10%). Behind them sits our research into pricing data, clinical evidence, user reviews and publicly available information. Those weights then combine into one overall score out of 10.
The six-dimension methodology computes each score on its own, and no commercial relationship ever moves a provider's underlying number. Every provider's full score sits on its card for you to check. Some providers do hold affiliate agreements with us, which means a commission reaches us if you click through and buy. On the lists carrying the highest commercial intent — the weight-loss injection and shot lists, the semaglutide and tirzepatide lists, the compounded and cheapest molecule lists, and the fitness-app list — affiliate partners take the top positions. Every other list runs in score order, or in price order on the cheapest lists. That placement is disclosed here, on our methodology page, and on our affiliate-disclosure page.
Sources & methodology — as of September 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings